WO1995032735A3 - Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease - Google Patents

Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease Download PDF

Info

Publication number
WO1995032735A3
WO1995032735A3 PCT/CA1995/000319 CA9500319W WO9532735A3 WO 1995032735 A3 WO1995032735 A3 WO 1995032735A3 CA 9500319 W CA9500319 W CA 9500319W WO 9532735 A3 WO9532735 A3 WO 9532735A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
infection
infected
cells
disease
Prior art date
Application number
PCT/CA1995/000319
Other languages
French (fr)
Other versions
WO1995032735A2 (en
Inventor
Geoffrey W Hoffmann
Original Assignee
Immune Network Res Ltd
Geoffrey W Hoffmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Network Res Ltd, Geoffrey W Hoffmann filed Critical Immune Network Res Ltd
Priority to AU25203/95A priority Critical patent/AU2520395A/en
Publication of WO1995032735A2 publication Critical patent/WO1995032735A2/en
Publication of WO1995032735A3 publication Critical patent/WO1995032735A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)

Abstract

Methods are provided for reducing the number of HIV-infected cells or HIV infection-susceptible cells of a host. Therapeutically this is achieved by exposing the cells to a V region selective element (VRSE) which binds to T cell receptors (TCR) of a V region defined family (VRDF) that is preferentially infected with HIV. The therapeutic VRSE can be an antibody which binds to the VRDF and is capable of causing cytotoxicity of infected and infection-susceptible cells, either alone, in conjunction with host factors, or fused to a toxin. The number of HIV-infection susceptible cells can be reduced prophylactically and in some circumstances therapeutically by immunization with an antibody or T cell receptor that induces an immune response that includes antibodies that bind to the TCR of a VRDF associated with HIV infection. The latter antibodies inhibit the viability of the infected or infection-susceptible cell. Means for diagnosing and treating diseases in which there is biasing of the immune repertoire are also provided, including those circumstances where very little may be known about the causative agent or the mechanism of pathogenesis. This is accomplished by selecting monoclonal antibodies for detecting antibody repertoire changes characteristic of a disease, thereby providing a diagnosis, and perturbing the immune system repertoire in the opposite direction to the direction of skewing that is characteristic of the disease or condition, thereby providing a means of prophylaxis or therapy.
PCT/CA1995/000319 1994-05-31 1995-05-31 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease WO1995032735A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25203/95A AU2520395A (en) 1994-05-31 1995-05-31 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25170794A 1994-05-31 1994-05-31
US08/251,707 1994-05-31

Publications (2)

Publication Number Publication Date
WO1995032735A2 WO1995032735A2 (en) 1995-12-07
WO1995032735A3 true WO1995032735A3 (en) 1996-02-29

Family

ID=22953068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1995/000319 WO1995032735A2 (en) 1994-05-31 1995-05-31 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease

Country Status (2)

Country Link
AU (1) AU2520395A (en)
WO (1) WO1995032735A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050240353A1 (en) * 2004-04-21 2005-10-27 Hoffmann Technologies Corporation Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008491A1 (en) * 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
EP0503916A1 (en) * 1991-03-11 1992-09-16 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
WO1993017694A1 (en) * 1992-03-09 1993-09-16 San Diego Regional Cancer Center An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008491A1 (en) * 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
EP0503916A1 (en) * 1991-03-11 1992-09-16 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
WO1993017694A1 (en) * 1992-03-09 1993-09-16 San Diego Regional Cancer Center An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
C. SUSAL ET AL.: "Complementarities and network interactions in AIDS.", JOURNAL OF AUTOIMMUNITY, vol. 6, no. 5, pages 601 - 610 *
G. HOFFMANN ET AL.: "An idiotypic network model of AIDS immunopathogenesis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 88, no. 8, 15 April 1991 (1991-04-15), WASHINGTON, DC, USA, pages 3060 - 3064 *
G. HOFFMANN: "An idiotypic network model of AIDS pathogenesis that is based on coselection (mutual positive selection) of HIV and helper T cells will be reviewed.", ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, vol. 41 supplement, 6 April 1994 (1994-04-06) - 8 April 1994 (1994-04-08), BUDAPEST, HUNGARY, pages 57 *
G. HOFFMANN: "Co-selection in immune network theory and in AIDS pathogenesis.", IMMUNOLOGY AND CELL BIOLOGY, vol. 72, no. 4, ADELAIDE, AUSTRALIA, pages 338 - 346 *
G. HOFFMANN: "On a role for co-selection between helper T cells and HIV in AIDS pathogenesis.", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 8 part 2, 15 April 1993 (1993-04-15), BALTIMORE, MD, USA, pages 102A *
G. HOFFMANN: "The T cell receptor and AIDS pathogenesis.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 41, no. 4, OXFORD, GB, pages 331 - 337 *
H. WANG ET AL.: "Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 22, no. 7, WEINHEIM, GERMANY, pages 1749 - 1755 *
N. REBAI ET AL.: "Analysis of the T-cell receptor beta-chain variable region (Vbeta) repertoire in monozygotic twins discordant for human immunodeficiency virus: Evidence for perturbations of specific Vbeta segments in CD4+ T cells of the virus-positive twins.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 91, no. 4, 15 February 1994 (1994-02-15), WASHINGTON, DC, USA, pages 1529 - 1533 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date
WO1995032735A2 (en) 1995-12-07
AU2520395A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
Espino et al. Sandwich enzyme-linked immunosorbent assay for detection of excretory secretory antigens in humans with fascioliasis
Santoro et al. Serodiagnosis of toxoplasma infection using a purified parasite protein (P30).
Savage et al. Antineutrophil cytoplasm antibodies in Kawasaki disease.
Corbeil et al. Adherence of Tritrichomonas foetus to bovine vaginal epithelial cells
Griffiths et al. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum
KR890014130A (en) Inhibitory and immunosuppressive combinations of B-lymphocytes in mammals.
Ekerfelt et al. Compartmentalization of antigen specific cytokine responses to the central nervous system in CNS borreliosis: secretion of IFN-γ predominates over IL-4 secretion in response to outer surface proteins of Lyme disease Borrelia spirochetes
EP0867189A3 (en) Monoclonal antibodies reactive with defined regions of the T cell antigen receptor
BR0013201A (en) Method of blocking an immune response to an external antigen in mammals through the use of an antagonist that binds to cd20, method of treating mammals, method of treating a disease of graft versus host or host versus graft in mammals, method of numbness of mammals awaiting transplantation and industrialized article
ATE161288T1 (en) MONOCLONAL ANTIBODIES AGAINST ENTEROHEMORRRHAGIC ESCHERICHIA COLI O157:H7 AND 026:H11 AND DETECTION METHOD
NO943625D0 (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type-I interferon
SE9401460D0 (en) Antigen / antibody specificity exhanger
DE59913716D1 (en) PROOF OF ACID-RESISTANT MICRO-ORGANISMS IN THE CHAIR
Lehmann et al. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea
US5626844A (en) Monoclonal antibody against ricin A chain
WO1995032735A3 (en) Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease
Jeong et al. A novel factor isolated from Actinobacillus actinomycetemcomitans stimulates mouse B cells and human peripheral blood mononuclear cells
Bahr et al. Antibody levels and in vitro lymphoproliferative responses to Streptococcus pyogenes erythrogenic toxin A and mitogen of patients with rheumatic fever
Yap The use of intravenous immunoglobulin for the treatment of infection: an overview
Nadel et al. Kawasaki disease
Devlin et al. Preferential Beef/Pork Insulin-binding Capacity: Radioimmunoelectrophoretic and Chromatographic Data in Patients with Dermal Reactions to Insulin
Ogier et al. Specific inhibition of Streptococcus mutans interactions with saliva components by monoclonal antibodies binding to different epitopes on the 74K cell wall saliva receptor (74K SR)
Aoki et al. Lethal shock is inducible by lipopolysaccharide but not by superantigen in mice with retrovirus-induced immunodeficiency syndrome.
Stankus et al. Nonprecipitating and electrophoretically restricted antibodies to carbohydrate of group A Streptococcus in the rat
Thirkill et al. Circulating and localized immune complexes in experimental mycoplasma-induced arthritis-associated ocular inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA